新一代的人治疗蛋白——Avimers  

A New Generation of Therapeutic Protein for Mankind—Avimers

作　　者：骆静辉[1] 方雪恩[1] 许宁一[1] 吴敏[2] 

机构地区：[1]浙江大学宁波理工学院生物与化学工程分院,浙江宁波315100 [2]浙江大学生命科学院,浙江杭州310027

出　　处：《药物生物技术》2007年第2期141-145,共5页Pharmaceutical Biotechnology

摘　　要：高亲和性多聚体(Avimers)是新发展的一种由多个亲和单体聚集在一起的治疗性蛋白质,它包含了多个对靶分子的亲和结构域,每个结构域都具有结合某种靶点的能力,Avimers也可以同时对一个或多个靶点进行结合。在结构上,Avimers跟抗体是没有关联的,但它将同样具有与抗体相似的生物活性作用,因而在某种程度上可以作为抗体的替代物。由于Avimers对目标物具有高亲合性、高专一性,且低分子质量和低免疫原性,在一定程度上可以弥补传统抗体治疗所带来的局限性,因而非常有希望出现于临床应用中。文章试从Avimers的结构特征、功能特性、设计方法和作用机理等方面阐述其目前的研究现状,同时展望了它的应用的前景。Avimers are a new class of small, assembled, and therapeutic proteins. It＇s single protein chains composed of modular binding domains - like beads on a string. Each bead is designed to bind to a particular target site. The string of beads can bind simultaneously to sites on a single protein target and/ or multiple protein targets. Known as multi-point attachment or avidity, this unique binding mechanism mimics the way that cells and molecules interact in the body and result in drugs with multiple functions and potent activity. Avimers have a unique structure that distinguishes them from antibodies, antibody fragments and other therapeutic proteins. But, as has been observed by researchers of the Avimer biotechnology corporation, Avidia, they can perform the same biological functions as the antibodies do, thus they may take the substitute of antibodies to certain degree. Avimers have the high affinity, the specificity, the low molecular weight and low immunity original to the sighting vane, so they should be very hopeful in the clinical application. Here its present research situation was summarized and its bright application in future was also forecasted.

关 键 词：高亲和性多聚体 亲和蛋白 A结构区域 噬菌体展示技术 

分 类 号：Q51[生物学—生物化学]